Immunology Phase 2 Deal Benchmarks (2026)

Median upfront of $547M with total deal values reaching $4.0B.

Median Upfront

$547M

Total Deal Value

$2.9B

Royalty Range

13.8%–23%

Territory Multiplier

Understanding Immunology Deal Benchmarks at Phase 2

Phase 2 Immunology licensing deals command a median upfront payment of $547M, with values ranging from $289M at the low end to $795M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the immunology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.8B to $4.0B, with a median of $2.9B. Royalty rates for immunology assets at this stage typically fall between 13.8% and 23% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Global territory applies a 1x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating global rights should calibrate upfront expectations and milestone structures accordingly.

PRO

Full Market Analysis

Detailed deal economics, territory impact analysis, and royalty structure breakdown.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Full Benchmark Data

PRO

Full Benchmark Table

Low, median, and high ranges for upfront payments, total deal values, and royalty rates.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Comparable Deals

Year	Licensor	Licensee	Upfront	Total Value	Deal Type
2024	Regeneron	Sanofi	$0M	$13.0B	collaboration
2023	Pharming Group	CSPC Pharmaceutical	$15M	$180M	licensing
2023	Almirall	AbbVie	$50M	$660M	licensing
2024	Connect Biopharma	Astellas Pharma	$25M	$350M	licensing
2021	Alexion Pharmaceuticals	AstraZeneca	$39.0B	$39.0B	acquisition
2024	Alnylam Pharmaceuticals	Roche	$310M	$2.5B	collaboration
2024	Apellis Pharmaceuticals	N/A (standalone)	$0M	$800M	licensing
2020	Principia Biopharma	Sanofi	$3.7B	$3.7B	acquisition
2024	Numab Therapeutics	AstraZeneca	$50M	$1.2B	licensing
2023	Kymera Therapeutics	Sanofi	$150M	$2.0B	collaboration

PRO

See All Comparable Deals

View 10 comparable Immunology transactions with upfront payments, total values, and deal structures.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Frequently Asked Questions

What is the average upfront payment for Phase 2 Immunology deals?

The median upfront payment for Phase 2 Immunology licensing deals is $547M, based on our analysis of comparable transactions. Values range from $289M for early-stage or less differentiated assets up to $795M for premium programs with strong clinical data or first-in-class mechanisms.

How does Global territory affect Immunology deal value?

Global rights carry a 1x multiplier relative to base deal economics. This means global immunology deals are valued at a discount compared to single-country rights, reflecting the combined market opportunity, regulatory pathway, and competitive dynamics of the territory.

What royalty rates are typical for Phase 2 Immunology licensing?

Royalty rates for Phase 2 immunology assets typically range from 13.8% to 23% of net sales. The exact rate depends on the licensor's contribution (IP, clinical data, manufacturing), deal structure (exclusive vs. co-exclusive), and the licensee's commercialization investment. Higher royalties often correspond to lower upfront payments, and vice versa.

PRO

More Expert Insights

Territory impact analysis, royalty negotiation strategies, and deal structure guidance.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

$72M upfront

Immunology · Preclinical · Global

$163M upfront

Immunology · Phase 1 · Global

$901M upfront

Immunology · Phase 3 · Global

$3.4B upfront

Immunology · Approved · Global

$258M upfront

Oncology · Phase 2 · Global

$232M upfront

Neurology/CNS · Phase 2 · Global

$589M upfront

Metabolic/Obesity · Phase 2 · Global

$301M upfront

Immunology · Phase 2 · US Only

Explore More

All Immunology Deals

View full therapeutic area benchmarks

Licensing Benchmarks Guide

2026 data from 1,900+ deals

Royalty Rate Benchmarks

Negotiation strategies by phase & modality

Run Custom Analysis

Pre-filled with Immunology · Phase 2

Run Your Own Benchmark

These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.

Open Deal Calculator

Cite This Data

APA

Ambrosia Ventures. (2026). Immunology Phase 2 Deal Benchmarks (2026). Retrieved from https://calculator.ambrosiaventures.co/data/immunology-phase-2-deals-global

HTML

<a href="https://calculator.ambrosiaventures.co/data/immunology-phase-2-deals-global">Immunology Phase 2 Deal Benchmarks (2026)</a> — Ambrosia Ventures (2026)

Embed Chart

Data sourced from 1,900+ verified biopharma transactions. Updated monthly.

Metric	Low	Median	High
Upfront Payment	$289M	$547M	$795M
Total Deal Value	$1.8B	$2.9B	$4.0B
Royalty Rate	13.8%	—	23%